Gogo Inc. Form 4 April 02, 2015

# FORM 4

#### **OMB APPROVAL**

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16. Form 4 or

January 31, Expires:

2005 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

(Print or Type Responses)

1(b).

(Last)

1. Name and Address of Reporting Person \* Payne Christopher D

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

Gogo Inc. [GOGO]

(Check all applicable)

(First)

(Street)

3. Date of Earliest Transaction (Month/Day/Year)

X\_ Director 10% Owner Officer (give title Other (specify below)

1250 N. ARLINGTON HEIGHTS ROAD, STE 500

4. If Amendment, Date Original

03/31/2015

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

(Instr. 8)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

(Instr. 4)

ITASCA, IL 60143

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if

(Month/Day/Year)

(Middle)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D)

5. Amount of Securities Beneficially Owned Following

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial (I) Ownership

(Instr. 4)

(A) or

(Instr. 3, 4 and 5)

Reported Transaction(s) (Instr. 3 and 4)

Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed Derivative Conversion (Month/Day/Year) Execution Date, if Security or Exercise any

5. Number 6. Date Exercisable and Transaction of Derivative Expiration Date Code Securities (Month/Day/Year)

7. Title and Amount of 8 **Underlying Securities** (Instr. 3 and 4)

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquire (A) or Dispose (D) (Instr. 3 and 5)	d of				
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	03/31/2015		A	655		<u>(1)</u>	<u>(1)</u>	Common Stock	655
Options (Right to Buy)	\$ 19.06	03/31/2015		A	2,261		03/31/2015	03/31/2025	Common Stock	2,261

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
copyrous o mac rame, mac and	Director	10% Owner	Officer	Other	
Payne Christopher D 1250 N. ARLINGTON HEIGHTS ROAD, STE 500 ITASCA, IL 60143	X				

## **Signatures**

/s/ Margee Elias, Attorney-in-Fact for Christopher D.
Payne
04/02/2015

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Deferred stock units that are settled in shares of common stock 90 days after the director ceases service as a director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. T: 0pt">

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 above regarding the Financing Transaction is incorporated herein by reference.

The Securities offered and sold under the Purchase Agreements to the Investors were offered and sold in reliance upon exemptions from registration under the Securities Act in reliance on Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder, as transactions by an issuer not involving a public offering. The Purchase Agreements contain representations to support the Company's reasonable belief that the Investors had access to information concerning the Company's operations and financial condition, the Investors did not acquire the Securities with a view to the distribution thereof in the absence of an effective registration statement or an applicable exemption

Reporting Owners 2

from registration, and that the Investors are "accredited investors" (as defined by Rule 501 under the Securities Act). The Company relied upon the representations made by the Investors pursuant to the Purchase Agreements in determining that such exemptions were available.

### Item 9.01 Financial Statements and Exhibits.

## (d) Exhibits.

		Filed		_			
Exhibit		Here				by Reference	
No.	Exhibit Description	with	Form	File No.	Exhibit	U	Filed By
4.1	Form of Warrant		8-K		4.1	August 10,	The Company
				000-25571		2010	
4.2	Warrant issued to	X					
	JMP Securities LLC,						
	dated August 12,						
	2010						
10.1	Securities Purchase		8-K		10.1	August 10,	The Company
	Agreement, dated			000-25571		2010	
	August 9, 2010, by						
	and among the						
	Company and the						
	U.S. Investors						
	signatories thereto						
10.2	Securities Purchase		8-K		10.2	August 10,	The Company
	Agreement, dated			000-25571		2010	1 2
	August 9, 2010, by						
	and between the						
	Company and the						
	Canadian Investor						
	signatory thereto						
10.3	Registration Rights	X					
10.5	Agreement, dated	21					
	August 12, 2010, by						
	•						
	and among the						
	Investors signatories						
	thereto						

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### RAPTOR PHARMACEUTICAL CORP.

Date: August 13, 2010 By: /s/ Christopher M. Starr

Name: Christopher M. Starr, Ph.D. Title: Chief Executive Officer

### Exhibit Index

Exhibit					corporated by Reference			
No.	Exhibit Description	with	Form	File No.		Filing Date	Filed By	
4.1	Form of Warrant		8-K		4.1	August 10,	The Company	
				000-25571		2010		
4.2	Warrant issued to	X						
	JMP Securities LLC,							
	dated August 12,							
	2010							
10.1	Securities Purchase		8-K		10.1	August 10,	The Company	
	Agreement, dated			000-25571		2010		
	August 9, 2010, by							
	and among the							
	Company and the							
	U.S. Investors							
10.2	signatories thereto		0.17		10.2	A	Th C	
10.2	Securities Purchase		8-K	000 25571	10.2	August 10,	The Company	
	Agreement, dated			000-25571		2010		
	August 9, 2010, by and between the							
	Company and the Canadian Investor							
10.3	signatory thereto	X						
10.5	Registration Rights Agreement, dated	Λ						
	August 12, 2010, by							
	and among the							
	Investors signatories							
	thereto							